Definitive Contract HHSD200201800009C
Award Date
12/12/17
Potential Completion Date
2/28/19
Potential Value
$12M
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC on December 23, 2016 for the 2017 adult flu season. The firm fixed price contract has a ceiling value of $12,408,000.00 and a performance period ending February 28, 2018. The contract does not have a set-aside designation. GlaxoSmithKline, a pharmaceutical company, has provided a range of products to U.S. government agencies through federal contracts, including influenza...
This federal contract award, valued at $102,189,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines. The contract is a definitive, firm fixed-price contract without any set-aside designation. Glaxosmithkline has provided a range of pharmaceutical goods and services to various U.S. government agencies, including vaccines, antiviral medications, and COVID-19 treatments. The company also...
This is a $84,710,550.00 definitive contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Glaxosmithkline, LLC for the provision of adult vaccines. The contract is a firm fixed price arrangement with no set-aside designation. Glaxosmithkline is a pharmaceutical company that supplies a range of vaccines and antiviral medications to various U.S. government agencies through federal contracts. This award supports the CDC's adult immunization...
This is a $69,857,670.45 firm fixed price contract awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, doing business as Glaxosmithkline, for 2016 pandemic influenza preparedness efforts. The contract has a completion date of February 28, 2017 and was awarded on December 18, 2015. There was no set-aside designation used. Glaxosmithkline is a pharmaceutical company that provides vaccines, antiviral medications, and other products to various federal agencies,...
The U.S. government agency, the Medical Supply Chain, has awarded a $1,400.00 firm fixed price delivery order contract to Glaxosmithkline, LLC, a pharmaceutical company, for the provision of influenza virus vaccines. This contract has no set-aside designation and the performance will take place at Glaxosmithkline's facilities in Durham, North Carolina. Glaxosmithkline has also received several other federal contracts and grants to supply a range of pharmaceutical products and services, including...
This federal contract award was made by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC, a pharmaceutical company that provides vaccines, antiviral medications, and other pharmaceutical products to U.S. government agencies. The contract has a total ceiling value of $213,831.06 and was awarded on a firm fixed price basis with no set-aside designation. It is a delivery order under GlaxoSmithKline's existing General Services Administration Federal Supply Schedule...
This is a $2,603,484.86 firm fixed price purchase order awarded by the U.S. Department of Health and Human Services to Glaxosmithkline, LLC for the supply of influenza vaccine for the 2015-2016 season. The contract did not have a set-aside designation. Glaxosmithkline, a pharmaceutical company that provides vaccines and other products to federal agencies, was the prime contractor on this award. The contract was performed at Glaxosmithkline's facilities in Research Triangle Park, North...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $1,085,922,457.04 firm fixed price contract to Glaxosmithkline, LLC for the provision of vaccines for children. The contract, which did not have a set-aside designation, has a performance period ending on March 31, 2018. Glaxosmithkline, a foreign-owned for-profit pharmaceutical company, provides a range of vaccines, antivirals, and other pharmaceutical products to federal agencies including the...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Glaxosmithkline, LLC, a pharmaceutical company, for the supply of 8502637428 influenza virus vaccine. The $100,660.00 contract has a performance period ending on November 30, 2015 and was not set aside for any socioeconomic category. Glaxosmithkline holds multiple federal contract vehicles with agencies like the Department of Veterans Affairs, Centers for Disease Control and Prevention, and DLA to...
This federal contract award, valued at $9,033,542.56, was issued by the Defense Department's Medical Supply Chain agency to Glaxosmithkline, LLC, a pharmaceutical company, for the delivery of influenza virus vaccines. The contract has a firm fixed price structure and an ultimate completion date of October 17, 2016. It is not designated as a set-aside contract. Glaxosmithkline has provided a range of pharmaceutical goods and services to various federal agencies, including vaccines, antiviral...